An overview of thrombotic complications of old and new anticancer drugs
Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thromboti...
Uloženo v:
| Vydáno v: | Thrombosis research Ročník 191; s. S17 - S21 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Ltd
01.07.2020
|
| Témata: | |
| ISSN: | 0049-3848, 1879-2472, 1879-2472 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thrombotic complications, including intrinsic biological effect of malignant cells, accompanying operations, or the presence of indwellingvascular catheters, but there is also an additional risk caused by anticancer agents including chemotherapy and immunotherapy. In most cases the underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example by vascular endothelial growth factor inhibition). In addition, individual anticancer agents may have specific prothrombotic effects. As in recent years more intense anticancer drugs are administered, such as in myeloablative conditioning regimens preceding stem cell transplantation, thrombosis and in particular thrombotic microangiopathy are a more frequent complication in anticancer treatment. |
|---|---|
| AbstractList | ABSTRACTThrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thrombotic complications, including intrinsic biological effect of malignant cells, accompanying operations, or the presence of indwellingvascular catheters, but there is also an additional risk caused by anticancer agents including chemotherapy and immunotherapy. In most cases the underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example by vascular endothelial growth factor inhibition). In addition, individual anticancer agents may have specific prothrombotic effects. As in recent years more intense anticancer drugs are administered, such as in myeloablative conditioning regimens preceding stem cell transplantation, thrombosis and in particular thrombotic microangiopathy are a more frequent complication in anticancer treatment. Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thrombotic complications, including intrinsic biological effect of malignant cells, accompanying operations, or the presence of indwellingvascular catheters, but there is also an additional risk caused by anticancer agents including chemotherapy and immunotherapy. In most cases the underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example by vascular endothelial growth factor inhibition). In addition, individual anticancer agents may have specific prothrombotic effects. As in recent years more intense anticancer drugs are administered, such as in myeloablative conditioning regimens preceding stem cell transplantation, thrombosis and in particular thrombotic microangiopathy are a more frequent complication in anticancer treatment. Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thrombotic complications, including intrinsic biological effect of malignant cells, accompanying operations, or the presence of indwellingvascular catheters, but there is also an additional risk caused by anticancer agents including chemotherapy and immunotherapy. In most cases the underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example by vascular endothelial growth factor inhibition). In addition, individual anticancer agents may have specific prothrombotic effects. As in recent years more intense anticancer drugs are administered, such as in myeloablative conditioning regimens preceding stem cell transplantation, thrombosis and in particular thrombotic microangiopathy are a more frequent complication in anticancer treatment.Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other manifestations such as arterial thrombosis or thrombotic microangiopathy may occur. Cancer itself is not only associated with risk factors for thrombotic complications, including intrinsic biological effect of malignant cells, accompanying operations, or the presence of indwellingvascular catheters, but there is also an additional risk caused by anticancer agents including chemotherapy and immunotherapy. In most cases the underlying pathogenetic factor that contributes to the thrombotic risk associated with chemotherapy is endothelial cell injury (or loss of protection of endothelial integrity, for example by vascular endothelial growth factor inhibition). In addition, individual anticancer agents may have specific prothrombotic effects. As in recent years more intense anticancer drugs are administered, such as in myeloablative conditioning regimens preceding stem cell transplantation, thrombosis and in particular thrombotic microangiopathy are a more frequent complication in anticancer treatment. |
| Author | Sivapalaratnam, Suthesh Levi, Marcel |
| Author_xml | – sequence: 1 givenname: Marcel surname: Levi fullname: Levi, Marcel email: marcel.levi@nhs.net organization: Department of Medicine, University College London Hospitals NHS Foundation Trust, London, UK – sequence: 2 givenname: Suthesh surname: Sivapalaratnam fullname: Sivapalaratnam, Suthesh organization: Department of Haemato-Oncology, Barts NHS Trust, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32736772$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1O3TAQRq2KqlxoH4EqS1ik9V_iRAgQQi2thNRF2VvOeEINiX2xEyrevs690AVSRVde-HzHnm_2yI4PHgk5YPQTo6z-_JNS2Zaikc0hp0eCipaV7A1ZsUa1JZeK75DVX2SX7KV0SylTrK3ekV3BlaiV4ityee6L8IDxweHvIvTF9CuGsQuTgwLCuB4cmMkFn5a7MNjCeFv4jBqfEeMBY2HjfJPek7e9GRJ-eDr3yfXXL9cX38qrH5ffL86vSqgknUoAZTlCD7LDjte1ZZi_ClQxqnq0koGsaoU9VlZI6Ppedo3oGsNrwSjvxD453GrXMdzPmCY9ugQ4DMZjmJPmkreqqYQSGf34hM7diFavoxtNfNTPs2fgeAtADClF7DW4aTPtFI0bNKN6aVpvmtZLjZpTvWlas5yuXqSfH3gtd7bNYW4ptx51Aoe5SOsiwqRtcK8aTl8YYHA-b2O4w0dMt2GOPq9AM524plvJ4uB0Y1gEJ_8W_McH_gAaFL2A |
| CitedBy_id | crossref_primary_10_1186_s12885_024_12099_8 crossref_primary_10_1097_COC_0000000000000981 crossref_primary_10_1016_j_jaccao_2024_04_006 crossref_primary_10_1007_s00044_022_02916_9 crossref_primary_10_1016_j_thromres_2021_06_018 crossref_primary_10_1002_rth2_12368 crossref_primary_10_1007_s00134_023_06980_6 crossref_primary_10_1016_j_nantod_2025_102677 crossref_primary_10_1016_j_thromres_2021_12_017 crossref_primary_10_3390_molecules26040852 crossref_primary_10_1097_HS9_0000000000000571 crossref_primary_10_1002_jha2_1090 crossref_primary_10_1172_jci_insight_190311 crossref_primary_10_1002_aoc_7784 crossref_primary_10_1016_j_cllc_2024_04_004 crossref_primary_10_1016_j_vph_2023_107223 crossref_primary_10_1016_j_thromres_2022_10_020 crossref_primary_10_3389_fcvm_2021_694711 crossref_primary_10_1016_j_thromres_2021_11_024 crossref_primary_10_5812_ijpr_143213 crossref_primary_10_1002_nano_202400030 crossref_primary_10_1016_j_tracli_2025_09_004 crossref_primary_10_1161_ATVBAHA_120_314694 |
| Cites_doi | 10.1159/000046585 10.1634/theoncologist.8-4-381 10.1046/j.1538-7933.2003.00573.x 10.1007/BF00135874 10.1200/JCO.1997.15.11.3378 10.1200/JCO.2002.11.135 10.1002/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E 10.1002/cncr.10847 10.1038/ki.1989.132 10.1056/NEJMoa025313 10.1200/JCO.2002.20.6.1657 10.1111/j.1365-2141.1970.tb01433.x 10.1073/pnas.92.18.8205 10.1182/blood.V72.2.451.451 10.1016/S0049-3848(16)30101-3 10.1084/jem.20020077 10.1097/00003246-200205001-00008 10.7326/0003-4819-101-1-41 10.1172/JCI117451 10.1055/s-2007-994916 10.1160/TH02-11-0283 10.1161/01.ATV.0000030186.66672.36 10.1182/blood-2002-01-0108 10.1016/S0140-6736(99)05036-9 10.1053/j.ajkd.2015.02.340 10.1016/S0305-7372(03)80006-3 10.1056/NEJMoa073149 10.1038/nm0296-209 10.1159/000046589 10.1097/00063198-199807000-00007 10.1055/s-0039-1687890 10.1182/blood.V98.5.1614 10.1016/j.thromres.2018.01.016 10.1200/JCO.2000.18.17.3078 10.1200/JCO.2012.42.4358 10.1182/blood.V77.8.1837.1837 10.1177/1358863X14568705 10.1177/1078155216628324 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E 10.1016/S0049-3848(01)00235-3 10.1182/blood.V73.7.2018.2018 10.1016/j.nephro.2017.01.016 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Ltd Elsevier Ltd 2020 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2020 Elsevier Ltd – notice: Elsevier Ltd – notice: 2020 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/S0049-3848(20)30391-1 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-2472 |
| EndPage | S21 |
| ExternalDocumentID | 32736772 10_1016_S0049_3848_20_30391_1 S0049384820303911 1_s2_0_S0049384820303911 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ~G- ~HD 0SF AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR ZA5 9DU AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c540t-cc7d2ecfc4beb266d1e472c07107fed41c4567efe5d34cbff4b83b8a263102b3 |
| ISICitedReferencesCount | 23 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000555314400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0049-3848 1879-2472 |
| IngestDate | Sun Nov 09 12:04:08 EST 2025 Wed Feb 19 02:30:18 EST 2025 Sat Nov 29 07:27:31 EST 2025 Tue Nov 18 22:24:46 EST 2025 Fri Feb 23 02:47:01 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Oct 14 19:36:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Thrombotic microangiopathy Anti-VEGF treatment Chemotherapy Thrombosis Cancer Endothelium |
| Language | English |
| License | 2020 Elsevier Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c540t-cc7d2ecfc4beb266d1e472c07107fed41c4567efe5d34cbff4b83b8a263102b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32736772 |
| PQID | 2429785373 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2429785373 pubmed_primary_32736772 crossref_citationtrail_10_1016_S0049_3848_20_30391_1 crossref_primary_10_1016_S0049_3848_20_30391_1 elsevier_sciencedirect_doi_10_1016_S0049_3848_20_30391_1 elsevier_clinicalkeyesjournals_1_s2_0_S0049384820303911 elsevier_clinicalkey_doi_10_1016_S0049_3848_20_30391_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-01 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Thrombosis research |
| PublicationTitleAlternate | Thromb Res |
| PublicationYear | 2020 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Guinan, Tarbell, Niemeyer (bb0055) 1988; 72 Hettiarachchi, Prins, Lensing, Buller (bb0240) 1998; 4 Maurer, Herndon, Hollis (bb0250) 1997; 15 Levi (bb0225) 2016; 140 Desai, Vogelzang, Rini (bb0085) 2002; 95 G.H. Neild, Haemolytic-uraemic syndrome in practice, Lancet 343 (1994) 398–401. [17] M. Zangari, E. Anaissie, B. Barlogie, et al., Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, Blood 98 (2001) 1614–1615. Collins, Gutteridge, O’Driscoll (bb0135) 1992; 10 Levi (bb0025) 2018; 164 Kakkar, Levine, Pinedo (bb0230) 2003; 8 Kuenen, Levi, Meijers (bb0200) 2002; 22 Pettitt, Clark (bb0040) 1994; 14 Bromberg, Konigsberg, Madison (bb0115) 1995; 92 Donati, Falanga (bb0105) 2001; 106 Mitchell, Andrew, Hanna (bb0180) 2003; 90 Levi (bb0020) 2019; 45 Kuenen, Rosen, Smit (bb0090) 2002; 20 Snyder, Mittelman, Oral (bb0050) 1993; 71 Kaushal, Kaushal, Melkaveri, Mehta (bb0210) 2004; 2 Bona (bb0095) 1999; 25 Kakkar (bb0255) 2003; 29 Zhang, Deng, Luther (bb0120) 1994; 94 Fisher, Dignam, Wolmark (bb0195) 1999; 353 Lee, Levine, Baker (bb0235) 2003; 349 Antignac, Gubler, Leverger (bb0065) 1989; 35 Lebeau, Chastang, Brechot (bb0245) 1994; 74 Chappell, Keeling, Prentice, Sweny (bb0060) 1988; 3 Walshe, Malak, Eagan, Sepkowitz (bb0100) 2002; 20 Hutten, Prins, Gent (bb0215) 2000; 18 Grange, Coppo (bb0165) 2017; 13 Seng, Liu, Chiu (bb0190) 2012; 30 Rabinowe, Soiffer, Tarbell (bb0070) 1991; 77 Brain, Azzopardi, Baker (bb0125) 1970; 18 Conway, Van de Wouwer, Pollefeyt (bb0145) 2002; 196 Prandoni, Lensing, Piccioli (bb0220) 2002; 100 Conway, Rosenberg (bb0150) 1988; 8 Zangari, Anaissie, Barlogie (bb0205) 2001; 98 Garcia, Atallah (bb0175) 2017 Cunningham, Starling, Rao (bb0185) 2008; 358 Doll, Yarbro (bb0035) 1992; 19 Kwaan, Gordon (bb0015) 2001; 106 JacksonM, Rose, Graff (bb0160) 1984; 101 Levi, ten Cate, van der Poll (bb0155) 2002; 30 Oppelt, Betbadal, Nayak (bb0170) 2015; 20 Holler, Kolb, Hiller (bb0130) 1989; 73 Juckett, Perry, Daniels, Weisdorf (bb0075) 1991; 7 Izzedine, Perazella (bb0045) 2015; 66 Levi (bb0005) 2001; 31 Contrino, Hair, Kreutzer, Rickles (bb0110) 1996; 2 Otten, Prins (bb0030) 2001; 102 Bertomeu, Gallo, Lauri (bb0140) 1990; 8 Lee, Levine (bb0010) 2003; 107 JacksonM (10.1016/S0049-3848(20)30391-1_bb0160) 1984; 101 Lee (10.1016/S0049-3848(20)30391-1_bb0235) 2003; 349 Kuenen (10.1016/S0049-3848(20)30391-1_bb0200) 2002; 22 Bromberg (10.1016/S0049-3848(20)30391-1_bb0115) 1995; 92 Conway (10.1016/S0049-3848(20)30391-1_bb0150) 1988; 8 Garcia (10.1016/S0049-3848(20)30391-1_bb0175) 2017 Desai (10.1016/S0049-3848(20)30391-1_bb0085) 2002; 95 Conway (10.1016/S0049-3848(20)30391-1_bb0145) 2002; 196 Pettitt (10.1016/S0049-3848(20)30391-1_bb0040) 1994; 14 Levi (10.1016/S0049-3848(20)30391-1_bb0025) 2018; 164 Walshe (10.1016/S0049-3848(20)30391-1_bb0100) 2002; 20 Fisher (10.1016/S0049-3848(20)30391-1_bb0195) 1999; 353 Donati (10.1016/S0049-3848(20)30391-1_bb0105) 2001; 106 Chappell (10.1016/S0049-3848(20)30391-1_bb0060) 1988; 3 Kuenen (10.1016/S0049-3848(20)30391-1_bb0090) 2002; 20 Juckett (10.1016/S0049-3848(20)30391-1_bb0075) 1991; 7 Levi (10.1016/S0049-3848(20)30391-1_bb0225) 2016; 140 Levi (10.1016/S0049-3848(20)30391-1_bb0155) 2002; 30 Seng (10.1016/S0049-3848(20)30391-1_bb0190) 2012; 30 Lee (10.1016/S0049-3848(20)30391-1_bb0010) 2003; 107 Maurer (10.1016/S0049-3848(20)30391-1_bb0250) 1997; 15 Oppelt (10.1016/S0049-3848(20)30391-1_bb0170) 2015; 20 Levi (10.1016/S0049-3848(20)30391-1_bb0020) 2019; 45 Mitchell (10.1016/S0049-3848(20)30391-1_bb0180) 2003; 90 Brain (10.1016/S0049-3848(20)30391-1_bb0125) 1970; 18 Kakkar (10.1016/S0049-3848(20)30391-1_bb0230) 2003; 8 Lebeau (10.1016/S0049-3848(20)30391-1_bb0245) 1994; 74 Bertomeu (10.1016/S0049-3848(20)30391-1_bb0140) 1990; 8 Levi (10.1016/S0049-3848(20)30391-1_bb0005) 2001; 31 Zangari (10.1016/S0049-3848(20)30391-1_bb0205) 2001; 98 Guinan (10.1016/S0049-3848(20)30391-1_bb0055) 1988; 72 Hettiarachchi (10.1016/S0049-3848(20)30391-1_bb0240) 1998; 4 Izzedine (10.1016/S0049-3848(20)30391-1_bb0045) 2015; 66 Bona (10.1016/S0049-3848(20)30391-1_bb0095) 1999; 25 Holler (10.1016/S0049-3848(20)30391-1_bb0130) 1989; 73 Doll (10.1016/S0049-3848(20)30391-1_bb0035) 1992; 19 Kwaan (10.1016/S0049-3848(20)30391-1_bb0015) 2001; 106 Contrino (10.1016/S0049-3848(20)30391-1_bb0110) 1996; 2 Zhang (10.1016/S0049-3848(20)30391-1_bb0120) 1994; 94 Snyder (10.1016/S0049-3848(20)30391-1_bb0050) 1993; 71 10.1016/S0049-3848(20)30391-1_bb0080 Cunningham (10.1016/S0049-3848(20)30391-1_bb0185) 2008; 358 Grange (10.1016/S0049-3848(20)30391-1_bb0165) 2017; 13 Otten (10.1016/S0049-3848(20)30391-1_bb0030) 2001; 102 Kaushal (10.1016/S0049-3848(20)30391-1_bb0210) 2004; 2 Hutten (10.1016/S0049-3848(20)30391-1_bb0215) 2000; 18 Collins (10.1016/S0049-3848(20)30391-1_bb0135) 1992; 10 Rabinowe (10.1016/S0049-3848(20)30391-1_bb0070) 1991; 77 Kakkar (10.1016/S0049-3848(20)30391-1_bb0255) 2003; 29 Prandoni (10.1016/S0049-3848(20)30391-1_bb0220) 2002; 100 Antignac (10.1016/S0049-3848(20)30391-1_bb0065) 1989; 35 |
| References_xml | – volume: 106 start-page: 18 year: 2001 end-page: 24 ident: bb0105 article-title: Pathogenetic mechanisms of thrombosis in malignancy publication-title: Acta Haematol. – volume: 3 start-page: 339 year: 1988 end-page: 347 ident: bb0060 article-title: Haemolytic uraemic syn- drome after bone marrow transplantation: an adverse effect of total body irradiation? publication-title: Bone Marrow Transplant. – volume: 358 start-page: 36 year: 2008 end-page: 46 ident: bb0185 article-title: Capecitabine and oxaliplatin for advanced esophagogastric cancer publication-title: N. Engl. J. Med. – volume: 102 start-page: V187 year: 2001 end-page: V194 ident: bb0030 article-title: Venous thromboembolism and occult malignancy publication-title: Thromb. Res. – volume: 95 start-page: 1629 year: 2002 end-page: 1636 ident: bb0085 article-title: A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma publication-title: Cancer – volume: 18 start-page: 3078 year: 2000 end-page: 3083 ident: bb0215 article-title: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis publication-title: J. Clin. Oncol. – volume: 30 start-page: 4416 year: 2012 end-page: 4426 ident: bb0190 article-title: Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis publication-title: J. Clin. Oncol. – volume: 8 start-page: 381 year: 2003 end-page: 388 ident: bb0230 article-title: Venous thrombosis in cancer patients: insights from the FRONTLINE survey publication-title: Oncologist – volume: 66 start-page: 857 year: 2015 end-page: 868 ident: bb0045 article-title: Thrombotic microangiopathy, cancer, and cancer drugs publication-title: Am. J. Kidney Dis. – volume: 101 start-page: 41 year: 1984 end-page: 44 ident: bb0160 article-title: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy publication-title: Ann. Intern. Med. – volume: 73 start-page: 2018 year: 1989 end-page: 2024 ident: bb0130 article-title: Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation publication-title: Blood – volume: 353 start-page: 1993 year: 1999 end-page: 2000 ident: bb0195 article-title: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 ran- domised controlled trial publication-title: Lancet – volume: 196 start-page: 565 year: 2002 end-page: 577 ident: bb0145 article-title: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen- activated protein kinase pathways publication-title: J. Exp. Med. – volume: 92 start-page: 8205 year: 1995 end-page: 8209 ident: bb0115 article-title: Tissue factor promotes mela- noma metastasis by a pathway independent of blood coagulation publication-title: Proc. Natl. Acad. Sci. USA – volume: 8 start-page: 511 year: 1990 end-page: 518 ident: bb0140 article-title: Chemotherapy enhances endothelial cell reactivity to platelets publication-title: Clin. Exp. Metastasis – volume: 77 start-page: 1837 year: 1991 end-page: 1844 ident: bb0070 article-title: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies publication-title: Blood – volume: 10 start-page: 499 year: 1992 end-page: 506 ident: bb0135 article-title: von Willebrand factor as a marker of endothelial cell activation following BMT publication-title: Bone Marrow Transplant – volume: 72 start-page: 451 year: 1988 end-page: 455 ident: bb0055 article-title: Intravascular hemolysis and renal insufficiency after bone marrow transplantation publication-title: Blood – volume: 30 start-page: S220 year: 2002 end-page: S224 ident: bb0155 article-title: Endothelium: interface between coagulation and inflammation publication-title: Crit. Care Med – volume: 90 start-page: 235 year: 2003 end-page: 244 ident: bb0180 article-title: Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-aspar- aginase for acute lymphoblastic leukemia. Results of the PAARKA study publication-title: Thromb. Haemost. – volume: 349 start-page: 146 year: 2003 end-page: 153 ident: bb0235 article-title: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer publication-title: N. Engl. J. Med. – volume: 25 start-page: 147 year: 1999 end-page: 155 ident: bb0095 article-title: Thrombotic complications of central venous catheters in cancer patients publication-title: Semin. Thromb. Hemost. – volume: 164 start-page: S77 year: 2018 end-page: S81 ident: bb0025 article-title: Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers publication-title: Thromb. Res. – volume: 107 start-page: I17 year: 2003 end-page: I21 ident: bb0010 article-title: Venous thromboembolism and cancer: risks and outcomes publication-title: Circulation – volume: 29 start-page: 23 year: 2003 end-page: 26 ident: bb0255 article-title: An expanding role for antithrombotic therapy in cancer patients publication-title: Cancer Treat. Rev. – volume: 22 start-page: 1500 year: 2002 end-page: 1505 ident: bb0200 article-title: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 98 start-page: 1614 year: 2001 end-page: 1615 ident: bb0205 article-title: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy publication-title: Blood – volume: 94 start-page: 1320 year: 1994 end-page: 1327 ident: bb0120 article-title: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice publication-title: J. Clin. Invest. – volume: 7 start-page: 405 year: 1991 end-page: 409 ident: bb0075 article-title: Hemolytic uremic syndrome fol- lowing bone marrow transplantation publication-title: Bone Marrow Transplant. – volume: 140 start-page: S66 year: 2016 end-page: S70 ident: bb0225 article-title: Management of cancer-associated disseminated intravascular coagulation publication-title: Thromb. Res. – volume: 15 start-page: 3378 year: 1997 end-page: 3387 ident: bb0250 article-title: Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study publication-title: J. Clin. Oncol. – volume: 74 start-page: 38 year: 1994 end-page: 45 ident: bb0245 article-title: Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group publication-title: Cancer – start-page: 135 year: 2017 end-page: 142 ident: bb0175 article-title: Antineoplastic agents and thrombotic microangiopathy publication-title: J. Oncol. Pharm. Pract. – volume: 4 start-page: 220 year: 1998 end-page: 225 ident: bb0240 article-title: Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thrombo- embolism publication-title: Curr. Opin. Pulm. Med. – volume: 71 start-page: 1882 year: 1993 end-page: 1892 ident: bb0050 article-title: Treatment of cancer chemotherapy- associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma publication-title: Cancer – volume: 8 start-page: 5588 year: 1988 end-page: 5592 ident: bb0150 article-title: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells publication-title: Mol. Cell. Biol. – volume: 106 start-page: 52 year: 2001 end-page: 56 ident: bb0015 article-title: Thrombotic microangiopathy in the cancer patient publication-title: Acta Haematol. – volume: 100 start-page: 3484 year: 2002 end-page: 3488 ident: bb0220 article-title: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis publication-title: Blood – volume: 2 start-page: 327 year: 2004 end-page: 334 ident: bb0210 article-title: Thalidomide protects endothe- lial cells from doxorubicin-induced apoptosis but alters cell morphology publication-title: J. Thromb. Haemost. – volume: 2 start-page: 209 year: 1996 end-page: 215 ident: bb0110 article-title: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease publication-title: Nature Med. – volume: 19 start-page: 580 year: 1992 end-page: 596 ident: bb0035 article-title: Vascular toxicity associated with antineoplastic agents publication-title: Semin. Oncol. – volume: 18 start-page: 183 year: 1970 end-page: 193 ident: bb0125 article-title: Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma publication-title: Br. J. Haematol. – volume: 20 start-page: 3276 year: 2002 end-page: 3281 ident: bb0100 article-title: Complication rates among can- cer patients with peripherally inserted central catheters publication-title: J. Clin. Oncol. – volume: 13 start-page: S109 year: 2017 end-page: S113 ident: bb0165 article-title: Thrombotic microangiopathies and antineoplastic agents publication-title: Nephrol. Therapeut. – reference: G.H. Neild, Haemolytic-uraemic syndrome in practice, Lancet 343 (1994) 398–401. [17] M. Zangari, E. Anaissie, B. Barlogie, et al., Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, Blood 98 (2001) 1614–1615. – volume: 45 start-page: 342 year: 2019 end-page: 347 ident: bb0020 article-title: Disseminated intravascular coagulation in cancer: an update publication-title: Semin. Thromb. Hemost. – volume: 20 start-page: 153 year: 2015 end-page: 161 ident: bb0170 article-title: Approach to chemotherapy-associated thrombosis publication-title: Vasc. Med. – volume: 14 start-page: 495 year: 1994 end-page: 504 ident: bb0040 article-title: Thrombotic microangiopathy following bone marrow trans- plantation publication-title: Bone Marrow Transplant. – volume: 20 start-page: 1657 year: 2002 end-page: 1667 ident: bb0090 article-title: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors publication-title: J. Clin. Oncol. – volume: 31 start-page: 47 year: 2001 end-page: 48 ident: bb0005 article-title: Cancer and DIC publication-title: Haemostasis – volume: 35 start-page: 1336 year: 1989 end-page: 1344 ident: bb0065 article-title: Delayed renal failure with exten- sive mesangiolysis following bone marrow transplantation publication-title: Kidney Int. – volume: 7 start-page: 405 year: 1991 ident: 10.1016/S0049-3848(20)30391-1_bb0075 article-title: Hemolytic uremic syndrome fol- lowing bone marrow transplantation publication-title: Bone Marrow Transplant. – volume: 106 start-page: 18 year: 2001 ident: 10.1016/S0049-3848(20)30391-1_bb0105 article-title: Pathogenetic mechanisms of thrombosis in malignancy publication-title: Acta Haematol. doi: 10.1159/000046585 – volume: 8 start-page: 381 year: 2003 ident: 10.1016/S0049-3848(20)30391-1_bb0230 article-title: Venous thrombosis in cancer patients: insights from the FRONTLINE survey publication-title: Oncologist doi: 10.1634/theoncologist.8-4-381 – volume: 14 start-page: 495 year: 1994 ident: 10.1016/S0049-3848(20)30391-1_bb0040 article-title: Thrombotic microangiopathy following bone marrow trans- plantation publication-title: Bone Marrow Transplant. – volume: 2 start-page: 327 year: 2004 ident: 10.1016/S0049-3848(20)30391-1_bb0210 article-title: Thalidomide protects endothe- lial cells from doxorubicin-induced apoptosis but alters cell morphology publication-title: J. Thromb. Haemost. doi: 10.1046/j.1538-7933.2003.00573.x – volume: 8 start-page: 511 year: 1990 ident: 10.1016/S0049-3848(20)30391-1_bb0140 article-title: Chemotherapy enhances endothelial cell reactivity to platelets publication-title: Clin. Exp. Metastasis doi: 10.1007/BF00135874 – volume: 15 start-page: 3378 year: 1997 ident: 10.1016/S0049-3848(20)30391-1_bb0250 article-title: Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1997.15.11.3378 – volume: 3 start-page: 339 year: 1988 ident: 10.1016/S0049-3848(20)30391-1_bb0060 article-title: Haemolytic uraemic syn- drome after bone marrow transplantation: an adverse effect of total body irradiation? publication-title: Bone Marrow Transplant. – volume: 20 start-page: 3276 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0100 article-title: Complication rates among can- cer patients with peripherally inserted central catheters publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.11.135 – volume: 71 start-page: 1882 year: 1993 ident: 10.1016/S0049-3848(20)30391-1_bb0050 article-title: Treatment of cancer chemotherapy- associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma publication-title: Cancer doi: 10.1002/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E – volume: 95 start-page: 1629 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0085 article-title: A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma publication-title: Cancer doi: 10.1002/cncr.10847 – volume: 35 start-page: 1336 year: 1989 ident: 10.1016/S0049-3848(20)30391-1_bb0065 article-title: Delayed renal failure with exten- sive mesangiolysis following bone marrow transplantation publication-title: Kidney Int. doi: 10.1038/ki.1989.132 – volume: 349 start-page: 146 year: 2003 ident: 10.1016/S0049-3848(20)30391-1_bb0235 article-title: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa025313 – volume: 20 start-page: 1657 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0090 article-title: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.20.6.1657 – volume: 107 start-page: I17 issue: Suppl 1 year: 2003 ident: 10.1016/S0049-3848(20)30391-1_bb0010 article-title: Venous thromboembolism and cancer: risks and outcomes publication-title: Circulation – volume: 18 start-page: 183 year: 1970 ident: 10.1016/S0049-3848(20)30391-1_bb0125 article-title: Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.1970.tb01433.x – volume: 92 start-page: 8205 year: 1995 ident: 10.1016/S0049-3848(20)30391-1_bb0115 article-title: Tissue factor promotes mela- noma metastasis by a pathway independent of blood coagulation publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.92.18.8205 – volume: 19 start-page: 580 year: 1992 ident: 10.1016/S0049-3848(20)30391-1_bb0035 article-title: Vascular toxicity associated with antineoplastic agents publication-title: Semin. Oncol. – volume: 72 start-page: 451 year: 1988 ident: 10.1016/S0049-3848(20)30391-1_bb0055 article-title: Intravascular hemolysis and renal insufficiency after bone marrow transplantation publication-title: Blood doi: 10.1182/blood.V72.2.451.451 – volume: 140 start-page: S66 issue: Suppl 1 year: 2016 ident: 10.1016/S0049-3848(20)30391-1_bb0225 article-title: Management of cancer-associated disseminated intravascular coagulation publication-title: Thromb. Res. doi: 10.1016/S0049-3848(16)30101-3 – volume: 196 start-page: 565 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0145 article-title: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen- activated protein kinase pathways publication-title: J. Exp. Med. doi: 10.1084/jem.20020077 – volume: 30 start-page: S220 issue: 5 Suppl year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0155 article-title: Endothelium: interface between coagulation and inflammation publication-title: Crit. Care Med doi: 10.1097/00003246-200205001-00008 – volume: 101 start-page: 41 year: 1984 ident: 10.1016/S0049-3848(20)30391-1_bb0160 article-title: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-101-1-41 – volume: 94 start-page: 1320 year: 1994 ident: 10.1016/S0049-3848(20)30391-1_bb0120 article-title: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice publication-title: J. Clin. Invest. doi: 10.1172/JCI117451 – volume: 25 start-page: 147 year: 1999 ident: 10.1016/S0049-3848(20)30391-1_bb0095 article-title: Thrombotic complications of central venous catheters in cancer patients publication-title: Semin. Thromb. Hemost. doi: 10.1055/s-2007-994916 – volume: 90 start-page: 235 year: 2003 ident: 10.1016/S0049-3848(20)30391-1_bb0180 article-title: Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-aspar- aginase for acute lymphoblastic leukemia. Results of the PAARKA study publication-title: Thromb. Haemost. doi: 10.1160/TH02-11-0283 – volume: 8 start-page: 5588 year: 1988 ident: 10.1016/S0049-3848(20)30391-1_bb0150 article-title: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells publication-title: Mol. Cell. Biol. – volume: 22 start-page: 1500 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0200 article-title: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.0000030186.66672.36 – volume: 100 start-page: 3484 year: 2002 ident: 10.1016/S0049-3848(20)30391-1_bb0220 article-title: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis publication-title: Blood doi: 10.1182/blood-2002-01-0108 – volume: 353 start-page: 1993 year: 1999 ident: 10.1016/S0049-3848(20)30391-1_bb0195 article-title: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 ran- domised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(99)05036-9 – volume: 66 start-page: 857 year: 2015 ident: 10.1016/S0049-3848(20)30391-1_bb0045 article-title: Thrombotic microangiopathy, cancer, and cancer drugs publication-title: Am. J. Kidney Dis. doi: 10.1053/j.ajkd.2015.02.340 – volume: 29 start-page: 23 issue: Suppl 2 year: 2003 ident: 10.1016/S0049-3848(20)30391-1_bb0255 article-title: An expanding role for antithrombotic therapy in cancer patients publication-title: Cancer Treat. Rev. doi: 10.1016/S0305-7372(03)80006-3 – volume: 358 start-page: 36 year: 2008 ident: 10.1016/S0049-3848(20)30391-1_bb0185 article-title: Capecitabine and oxaliplatin for advanced esophagogastric cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa073149 – volume: 2 start-page: 209 year: 1996 ident: 10.1016/S0049-3848(20)30391-1_bb0110 article-title: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease publication-title: Nature Med. doi: 10.1038/nm0296-209 – volume: 106 start-page: 52 year: 2001 ident: 10.1016/S0049-3848(20)30391-1_bb0015 article-title: Thrombotic microangiopathy in the cancer patient publication-title: Acta Haematol. doi: 10.1159/000046589 – volume: 10 start-page: 499 year: 1992 ident: 10.1016/S0049-3848(20)30391-1_bb0135 article-title: von Willebrand factor as a marker of endothelial cell activation following BMT publication-title: Bone Marrow Transplant – volume: 4 start-page: 220 year: 1998 ident: 10.1016/S0049-3848(20)30391-1_bb0240 article-title: Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thrombo- embolism publication-title: Curr. Opin. Pulm. Med. doi: 10.1097/00063198-199807000-00007 – volume: 45 start-page: 342 year: 2019 ident: 10.1016/S0049-3848(20)30391-1_bb0020 article-title: Disseminated intravascular coagulation in cancer: an update publication-title: Semin. Thromb. Hemost. doi: 10.1055/s-0039-1687890 – ident: 10.1016/S0049-3848(20)30391-1_bb0080 doi: 10.1182/blood.V98.5.1614 – volume: 164 start-page: S77 issue: Suppl 1 year: 2018 ident: 10.1016/S0049-3848(20)30391-1_bb0025 article-title: Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers publication-title: Thromb. Res. doi: 10.1016/j.thromres.2018.01.016 – volume: 98 start-page: 1614 year: 2001 ident: 10.1016/S0049-3848(20)30391-1_bb0205 article-title: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy publication-title: Blood doi: 10.1182/blood.V98.5.1614 – volume: 31 start-page: 47 issue: Suppl 1 year: 2001 ident: 10.1016/S0049-3848(20)30391-1_bb0005 article-title: Cancer and DIC publication-title: Haemostasis – volume: 18 start-page: 3078 year: 2000 ident: 10.1016/S0049-3848(20)30391-1_bb0215 article-title: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.17.3078 – volume: 30 start-page: 4416 year: 2012 ident: 10.1016/S0049-3848(20)30391-1_bb0190 article-title: Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.42.4358 – volume: 77 start-page: 1837 year: 1991 ident: 10.1016/S0049-3848(20)30391-1_bb0070 article-title: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies publication-title: Blood doi: 10.1182/blood.V77.8.1837.1837 – volume: 20 start-page: 153 year: 2015 ident: 10.1016/S0049-3848(20)30391-1_bb0170 article-title: Approach to chemotherapy-associated thrombosis publication-title: Vasc. Med. doi: 10.1177/1358863X14568705 – start-page: 135 year: 2017 ident: 10.1016/S0049-3848(20)30391-1_bb0175 article-title: Antineoplastic agents and thrombotic microangiopathy publication-title: J. Oncol. Pharm. Pract. doi: 10.1177/1078155216628324 – volume: 74 start-page: 38 year: 1994 ident: 10.1016/S0049-3848(20)30391-1_bb0245 article-title: Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group publication-title: Cancer doi: 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E – volume: 102 start-page: V187 year: 2001 ident: 10.1016/S0049-3848(20)30391-1_bb0030 article-title: Venous thromboembolism and occult malignancy publication-title: Thromb. Res. doi: 10.1016/S0049-3848(01)00235-3 – volume: 73 start-page: 2018 year: 1989 ident: 10.1016/S0049-3848(20)30391-1_bb0130 article-title: Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation publication-title: Blood doi: 10.1182/blood.V73.7.2018.2018 – volume: 13 start-page: S109 issue: Suppl 1 year: 2017 ident: 10.1016/S0049-3848(20)30391-1_bb0165 article-title: Thrombotic microangiopathies and antineoplastic agents publication-title: Nephrol. Therapeut. doi: 10.1016/j.nephro.2017.01.016 |
| SSID | ssj0017195 |
| Score | 2.4093227 |
| Snippet | Thrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other... ABSTRACTThrombosis is a common complication of cancer with a mean prevalence of 15%. Most commonly, this presents as venous thromboembolism; however, other... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S17 |
| SubjectTerms | Anti-VEGF treatment Cancer Chemotherapy Endothelium Hematology, Oncology, and Palliative Medicine Thrombosis Thrombotic microangiopathy |
| Title | An overview of thrombotic complications of old and new anticancer drugs |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0049384820303911 https://www.clinicalkey.es/playcontent/1-s2.0-S0049384820303911 https://dx.doi.org/10.1016/S0049-3848(20)30391-1 https://www.ncbi.nlm.nih.gov/pubmed/32736772 https://www.proquest.com/docview/2429785373 |
| Volume | 191 |
| WOSCitedRecordID | wos000555314400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-2472 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: AIEXJ dateStart: 20160601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bi9QwFA66K7Iv4t1ZdamgoEjXJk2b5HGQ9ca6CJ2HeQtNmuLK2C7TmWF_vieXtg7rsqvgS2doc4GcLydfknNB6KXOWCqwUrGhWMSUYBNzAwKhpc7qukxVql2c2WN2csLnc_EtuCt2Lp0Aaxp-fi7O_quo4R0I27rO_oW4h0bhBfwHocMTxA7Pawl-CgRwYzWA90ixeRB-qtbGZd02H4dv7cIFarVpxeHXnmoDBJZvq-U6nJ7_6LHk2rCxS0JwoOEQ-RgW1uDzo81grVGcbmARXtiw4o1HXGEt6bvvvx8ywI6yN0gNJ1-998toauS0KRVxyn2kzEPjFShn9saGbWtYn5Ar6MjCO2uG5bbwDtIXNLk_VCiGPoBvk-QVkBMb0j7G4_I1GBW6srYoSVwh2BPvEpYJ0HW7089H8y_D7RLDwme2CG2Pnl3vxg5fk-RN6OwyznLZnsRxk9lddCdsKqKpB8M9dMM099Htr8Fs4gH6OG2iHhNRW0cjJqItTNhvgIkIMBEBJqIRE5HDxEM0-3A0e_8pDhk0Yg1MfBVrzSpidK2pMgqoWIUNiEZbWslqU1GsgT8zU5usSqlWdU0VTxUvSQ6sn6j0Edpp2sY8QRGpVMZ0Buqa5jQ3hotEJ6LC3NCyzpWeINoPkdQhurxNcrKQoxkhjKy0IytJIt3ISjxBh0O1Mx9e5aoKeT_-svcdhtVOAmyuqsj-VNF0Yep2EsuOyERegNEE8aFmoKWebl6n0xc9RCSobXsXVzamXXcSmLFgQJVZOkGPPXaGAUhhS5HDrnf_3zt-ivbGafwM7ayWa_Mc3dKb1Wm3PEA32ZwfhFnxC48wv48 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+overview+of+thrombotic+complications+of+old+and+new+anticancer+drugs&rft.jtitle=Thrombosis+research&rft.au=Levi%2C+Marcel&rft.au=Sivapalaratnam%2C+Suthesh&rft.date=2020-07-01&rft.pub=Elsevier+Ltd&rft.issn=0049-3848&rft.eissn=1879-2472&rft.volume=191&rft.spage=S17&rft.epage=S21&rft_id=info:doi/10.1016%2FS0049-3848%2820%2930391-1&rft.externalDocID=S0049384820303911 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00493848%2FS0049384820X00132%2Fcov150h.gif |